NPI: 1508964123 · MISSOURI VALLEY, IA 51555 · Critical Access Hospital · NPI assigned 09/20/2006
Authorized official KUIPER, EVERT controls 20+ related entities in our dataset. Read more
| Authorized Official | KUIPER, EVERT (CEO - CHI HEALTH) |
| NPI Enumeration Date | 09/20/2006 |
Other providers sharing the same authorized official: KUIPER, EVERT
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 3,326 | $168K |
| 2019 | 3,261 | $160K |
| 2020 | 3,685 | $131K |
| 2021 | 3,068 | $145K |
| 2022 | 3,972 | $240K |
| 2023 | 4,506 | $286K |
| 2024 | 4,054 | $260K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 5,461 | 4,428 | $585K |
| 99284 | Emergency department visit for the evaluation and management, high severity | 1,362 | 1,089 | $244K |
| 80053 | Comprehensive metabolic panel | 4,658 | 4,105 | $164K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4,796 | 4,190 | $100K |
| 36415 | Collection of venous blood by venipuncture | 3,010 | 2,441 | $60K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 588 | 553 | $30K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 164 | 99 | $29K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 482 | 391 | $29K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1,675 | 796 | $26K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 184 | 177 | $20K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | 12 | 12 | $15K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 729 | 691 | $12K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 376 | 311 | $9K |
| J7120 | Ringers lactate infusion, up to 1000 cc | 74 | 69 | $7K |
| 71045 | Radiologic examination, chest; single view | 151 | 125 | $6K |
| 80050 | General health panel | 46 | 40 | $5K |
| J7030 | Infusion, normal saline solution , 1000 cc | 89 | 69 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 113 | 75 | $5K |
| 80061 | Lipid panel | 192 | 186 | $5K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 197 | 167 | $4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 423 | 393 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 138 | 128 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 74 | 69 | $4K |
| 84484 | 106 | 69 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 73 | 68 | $4K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 105 | 102 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | 46 | 37 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 13 | 12 | $2K |
| J3490 | Unclassified drugs | 226 | 143 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | 53 | 50 | $794.80 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 13 | 13 | $777.89 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 53 | 40 | $760.81 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 14 | 13 | $681.92 |
| 84443 | Thyroid stimulating hormone (TSH) | 29 | 28 | $611.63 |
| 83605 | 38 | 24 | $398.88 | |
| 86140 | 14 | 12 | $247.57 | |
| 86803 | 12 | 12 | $221.60 | |
| 81001 | 34 | 24 | $206.33 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 36 | 24 | $119.00 |
| 85610 | 13 | 12 | $95.76 |